SEMA7A

Across TCGA pan-cancer cohorts, SEMA7A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SEMA7A data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SEMA7A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SEMA7A expression acts as an unfavorable survival marker, although some lineages such as OV and HNSC show a favorable association.

LUAD, OV, and HNSC are the cancer types where SEMA7A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.434	0.751	.012	21	view →
OV	DFS	Median	All	0.923	0.515	.005	8	view →
HNSC	DFS	Tertile	IV	0.884	0.585	.011	7	view →
PDAC	DFS	Tertile	III,IV	0.588	0.975	.031	4	view →
GBM	OS	Median	All	0.220	0.501	.013	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SEMA7A–LUAD (OS)

Open the LUAD breakdown →